← Eichor
Study identifier: NCT06151236 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Condition: Merkel Cell Carcinoma  ·  Sponsor: Melanoma Institute Australia

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival

This description comes directly from the study's public registry record.

Talk to the study team

Monica Osorio  ·  + 61 2 9911 7296  ·  monica.osorio@melanoma.org.au

Always discuss trial participation with your own doctor first.

Locations (1)

Melanoma Institute AustraliaWollstonecraft, New South Wales, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06151236